OzempicvsZepbound

Ozempic's active ingredient, semaglutide, is a GLP-1 receptor agonist: it mimics glucagon-like peptide-1, a natural gut hormone released after eating. It prompts the pancreas to release more insulin when blood sugar is high, suppresses glucagon (a hormone that raises blood sugar), and slows stomach emptying. It also acts on appetite centers in the brain to reduce hunger and food intake, which is why many people eat less and lose some weight.

Zepbound's active drug, tirzepatide, is a once-weekly injection that activates two gut-hormone receptors at once: GLP-1 and GIP. This "dual agonist" design is what sets it apart from GLP-1-only drugs like Wegovy. By mimicking these hormones, it curbs appetite, increases fullness, and slows how fast the stomach empties, so most people eat less and feel satisfied longer. It also improves how the body releases insulin and handles blood sugar. The result is sustained calorie reduction without the constant hunger that derails many diets.

Across the SUSTAIN clinical trial program, Ozempic lowered A1C by roughly 1.0 to 1.8 percentage points depending on dose and starting level, with average weight reductions of about 6 to 14 lb (roughly 2.5 to 6.5 kg) at the 0.5 mg and 1 mg doses, and more at 2 mg. In the SUSTAIN-6 cardiovascular outcomes trial (3,297 patients with type 2 diabetes at high cardiovascular risk, published in NEJM in 2016), semaglutide reduced the primary composite of cardiovascular death, nonfatal heart attack, or nonfatal stroke by 26% versus placebo (6.6% vs 8.9%; hazard ratio 0.74, 95% CI 0.58 to 0.95). That composite benefit was driven mainly by a significant drop in nonfatal stroke; reductions in nonfatal heart attack and cardiovascular death individually were not statistically significant, and the trial notably found a higher rate of diabetic retinopathy complications in the semaglutide group. SUSTAIN-6 was designed as a safety (non-inferiority) trial that went on to show superiority on the composite. The separate 2024 FLOW trial showed a 24% reduction in a combined kidney-and-cardiovascular outcome, supporting the 2025 chronic kidney disease indication.

In the pivotal 72-week SURMOUNT-1 trial (2,539 adults with obesity or overweight, without type 2 diabetes; published in the New England Journal of Medicine in 2022), tirzepatide produced average body-weight reductions of about 16.0% at 5 mg, 21.4% at 10 mg, and 22.5% at 15 mg, versus roughly 2.4% with placebo. In the head-to-head SURMOUNT-5 trial (751 participants, 72 weeks, NEJM 2025), Zepbound beat Wegovy (semaglutide) with an average 20.2% weight loss versus 13.7%, a 47% greater relative reduction; about 31.6% of Zepbound users lost at least 25% of their body weight versus 16.1% on Wegovy. Zepbound is also FDA-approved (December 2024) for moderate-to-severe obstructive sleep apnea in adults with obesity, where the SURMOUNT-OSA program showed clinically meaningful reductions in the apnea-hypopnea index versus placebo. Individual results vary with dose, diet, and activity.

The most common side effects (reported in at least 5% of patients) are gastrointestinal: nausea (about 16-20%), vomiting, diarrhea, abdominal pain, and constipation. These are usually worst early on or after a dose increase and often ease over time; eating smaller, lower-fat meals can help. Serious but less common risks include pancreatitis (severe, persistent abdominal pain), gallbladder problems, acute kidney injury from dehydration, low blood sugar (especially when combined with insulin or sulfonylureas), worsening diabetic retinopathy, and allergic reactions. Ozempic carries an FDA boxed warning because semaglutide caused thyroid C-cell tumors in rodents; whether it does so in humans is unknown, but it is contraindicated in people with a personal or family history of medullary thyroid cancer or MEN 2. Tell your doctor about any persistent abdominal pain, vision changes, or signs of an allergic reaction.

The most common side effects are gastrointestinal and tend to appear during dose increases: nausea (reported in roughly 25-30% of users across the pivotal trials, and as high as the mid-30s in some studies), diarrhea, vomiting, constipation, abdominal pain, indigestion, and fatigue or injection-site reactions. These are usually mild-to-moderate and ease over time with slow titration, though they lead a small percentage of people to stop treatment. Less common but serious risks include pancreatitis (severe persistent abdominal pain), gallbladder problems including gallstones, acute kidney injury (often from dehydration due to vomiting or diarrhea), severe allergic reactions, and low blood sugar when combined with insulin or sulfonylureas. Zepbound carries an FDA boxed warning for thyroid C-cell tumors seen in rodent studies; whether it causes them in humans is unknown, but it is contraindicated in people with a personal or family history of medullary thyroid cancer or MEN 2. Seek care promptly for severe stomach pain, signs of an allergic reaction, or vision changes.

As of 2026, Ozempic's list price (WAC) is roughly $935 per month, and retail cash prices at major pharmacies run about $935-$969 per month without insurance or discounts. Novo Nordisk's NovoCare direct self-pay program offers cash prices of about $349/month for the 0.25, 0.5, and 1 mg pens and about $499/month for the 2 mg pen, with an introductory offer near $199/month for some new patients on the 0.25 mg and 0.5 mg doses through June 30, 2026. Commercially insured patients with coverage may pay as little as $25/month using the manufacturer savings card, but that lowest pricing is capped (up to $100/month in savings, for a limited number of months) and excludes people with government insurance. Medicare and Medicaid typically cover Ozempic for diabetes (but not for off-label weight loss), and a Patient Assistance Program provides free medication to qualifying low-income, uninsured patients. GoodRx-style coupons usually trim the retail price only modestly. Confirm current pricing and your own coverage before starting.

As of 2026, Zepbound's retail list price is roughly $1,086 per month for the pen, but few people pay that. Through Lilly's self-pay program (LillyDirect), single-dose vials run about $299/month for 2.5 mg, $399/month for 5 mg, and $449/month for 7.5 mg and higher strengths; for the higher doses you generally must refill within 45 days to keep that pricing, and it cannot be combined with insurance. If you have commercial insurance that covers Zepbound, Lilly's savings card can drop your copay to as little as $25/month (with a monthly and annual cap on total savings). Coverage is improving: many commercial plans now cover it for weight loss, and under a November 2025 agreement between Lilly and the U.S. government, Medicare is set to begin covering Zepbound for obesity with eligible beneficiaries paying no more than about $50/month, with phased rollout starting in 2026 and expanded Medicaid options for states. Coverage still varies by plan, so confirm your own benefits and current pricing before starting. Budget for ongoing monthly cost since it is a long-term medication.

Ozempic is FDA-approved for adults with type 2 diabetes to improve blood sugar control, to reduce major adverse cardiovascular events in those who also have established cardiovascular disease, and (since January 2025, based on the FLOW trial) to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular death in those with type 2 diabetes and chronic kidney disease. It is not approved for type 1 diabetes or for weight loss on its own. Do NOT use it if you or a family member has had medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or if you have had a serious allergic reaction to semaglutide. Use caution with a history of pancreatitis, diabetic retinopathy, or gallbladder disease, and discuss pregnancy plans with your doctor. Your prescriber makes the final eligibility call.

Zepbound is approved for adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) plus at least one weight-related condition such as high blood pressure, high cholesterol, or type 2 diabetes, and for moderate-to-severe obstructive sleep apnea in adults with obesity. It is meant to be used alongside a reduced-calorie diet and more physical activity. Do NOT use it if you or a family member has had medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or if you have had a serious allergic reaction to tirzepatide. It is not for use in pregnancy and is not approved for children. Use caution with a history of pancreatitis, gallbladder disease, kidney problems, or severe gastrointestinal disease, and tell your doctor if you take insulin or sulfonylureas (which raise low-blood-sugar risk). Your prescriber makes the final eligibility call.